Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 1, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 1, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/1/15 - Aequus Pharmaceuticals Launches Trading on OTCQB [Health & Beauty Close - Up]
Aequus Pharmaceuticals reported its stock is now trading on the OTCQB Venture Market in the United States under the symbol "AQSZF." Aequus will continue to trade on the Toronto Venture Exchange under its existing symbol "AQS". Aequus Pharmaceuticals is a Vancouver- based, specialty pharmaceutical company primarily focused on developing and commerci
9/1/15 - BioTime Management to Participate in Rodman & Renshaw 17th Annual Global Investment Conference [Manufacturing Close - Up]
BioTime reported that BioTime management will present at the Rodman& Renshaw 17th Annual Investment Conference in New York City from 3 to 3:25 p.m. EDT on Thursday, September 10. According to a release, investors will receive an update on BioTime and its subsidiaries. BioTime, a provider of regenerative medicine, is a clinical- stage biotechnology
9/1/15 - Bristol-Myers buys rights to acquire fibrosis drug developer Promedior
The deal gives Bristol-Myers access to Promedior's lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said yesterday. Massachusetts- based Promedior is backed by healthcare investors including British dru
9/1/15 - Patent Issued for Method of Preparation of an Oxidized Derivative of Hyaluronic Acid and a Method of Modification (USPTO 9109052)
By a News Reporter-Staff News Editor at Life Science Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Buffa, Radovan; Kettou, Sofiane; Pospisilova, Lucie; Huerta-Angeles, Gloria; Chladkova, Drahomira; Velebny, Vladimir, filed on December 10, 2010, was published online on August 18, 2015. The patent's assi
9/1/15 - Synedgen's Director for Pharmaceutical Manufacturing Publishes New Research
Research conducted by Synedgen Inc.' s Director for Pharmaceutical Manufacturing and colleagues from University of California Los Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer Research, and the Centers for Disease Control and Prevention appears in PLOS One, the world's first multidisciplinary Open Access...
9/1/15 - Temple & Fox Chase Cancer Center testing drug for cancer & bone marrow disorders
By a News Reporter-Staff News Editor at Life Science Weekly- Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine in Myelodysplastic syndromes and acute myelogenous leukemia. Jean-Pierre Issa, MD, D
9/1/15 - US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer
ViroMed Co., Ltd. today announced that the company has received an approval from the US FDA to launch a pivotal Phase III clinical trial utilizing VM202, a proprietary DNA based biopharmaceutical, for chronic non-healing ischemic diabetic foot ulcers. This is the first gene therapy trial specifically targeting ulcers which affects millions of peopl
8/31/15 - "Extracts of Perilla Frutescens Seeds and Their Pharmaceutical Uses" in Patent Application Approval Process (USPTO 20150224159)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Lo, Leah; Chiang, Win-Chin; Chen, Jui-Ching; Lin, Yu-Min; Wu, Chien-Chang; Lin, Che-Yi; Shih, Chien-Jen; Lin, Yu-Hsuan; Chen, Tzu-Chun; Huang, Yu-Hsiang, filed on February 3, 2015, was made available online on August 20, 2015, according to news repo
8/31/15 - "Natural Combination Hormone Replacement Formulations and Therapies" in Patent Application Approval Process (USPTO 20150224117)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H.R.; Irani, Neda; Amadio, Julia M., filed on April 20, 2015, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspo
8/31/15 - "Patient Reported Outcome Instrument" in Patent Application Approval Process (USPTO 20150223747)
By a News Reporter-Staff News Editor at Gastroenterology Week A patent application by the inventor Adelman, Daniel C., filed on September 5, 2013, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Alvine Pharmaceuticals, Inc
8/31/15 - 60 Degrees Pharmaceuticals to Begin Phase II Clinical Trials in Dengue Fever Patients
By a News Reporter-Staff News Editor at Clinical Trials Week 60 Degrees Pharmaceuticals,, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever
8/31/15 - Ablynx Announces Half-Year Results For 2015 [Global Data Point]
Dr Edwin Moses, CEO of Ablynx commented: "We have made substantial progress on all fronts, in our own fully-owned programmes and in our partnerships with leading pharmaceutical companies. We intend to apply for conditional approval of this product in Europe at the beginning of 2017 and, following a review of the commercialisation options, we have c
8/31/15 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Aug. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on August 17, 2015. The SEC file number is 0001179110-15-012224.. A U.S. Securities and Exchange Commission filing i
8/31/15 - Achillion Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Aug. 18, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achillion Pharmaceuticals Inc. was posted on August 18, 2015. The SEC file number is 0000904454-15-000528.. A U.S. Securities and Exchange Commission
8/31/15 - Achillion Pharmaceuticals Inc. Files SEC Form SC 13D, General Statement of Acquisition of Beneficial Ownership [Amend] (Aug. 19, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achillion Pharmaceuticals Inc. was posted on August 18, 2015. The SEC file number is 0000904454-15-000530.. A U.S. Securities and Exchange Commission
8/31/15 - ADMA Biologics Receives Patent Issuance Pertaining to the Treatment of Immunodeficiency
ADMA Biologics, Inc., a late-stage biopharmaceutical company, announced that the U.S. ADMA's goal is to ensure adherence to all FDA standards and produce an IG product with consistent lot to lot potency of polyclonal anti pathogen antibodies, "stated Adam Grossman, President and CEO of ADMA Biologics. About ADMA Biologics, Inc. ADMA is a late sta
8/31/15 - Aegerion Pharmaceuticals, Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (Aug. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aegerion Pharmaceuticals, Inc. was posted on August 17, 2015. The SEC file number is 0001193125-15-293352.. A U.S. Securities and Exchange Commission
8/31/15 - Aegerion Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report [Amend] (Aug. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aegerion Pharmaceuticals, Inc. was posted on August 17, 2015. The SEC file number is 0001193125-15-293346.. A U.S. Securities and Exchange Commission
8/31/15 - Aeolus Announces Publication of Study Showing AEOL 10150 Improves Memory and Protects Brain Damage in an Animal Model of Epilepsy
Aeolus Pharmaceuticals, Inc., a biotechnology company developing compounds to protect against radiological and chemical threats, announced the publication of a study in mice demonstrating that treatment with AEOL 10150 significantly improved memory and decreased nerve death after exposure to pilocarpine, an organophosphate used to simulate...
8/31/15 - AFT and Austrian Breast & Colorectal Cancer Study Group Open Global Phase 3 Trial of Targeted Therapy, IBRANCE (palbociclib) [Health & Beauty Close - Up]
The Alliance Foundation Trials, the Austrian Breast& Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study, or PALLAS. The company said the global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group, German Breast Group,...
8/31/15 - Agile Therapeutics Announces Completion of Patient Recruitment in Twirla(R) Phase 3 SECURE Clinical Trial
Agile Therapeutics, Inc. a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla , its investigational contraceptive patch.
8/31/15 - AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration [Global Data Point]
AGTC filed an Investigational New Drug application with the U.S. Food and Drug Administration in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues
8/31/15 - Alexion Pharmaceuticals Inc. Files SEC Form 424B7, Prospectus [Rule 424(B)(7)] (Aug. 13, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on August 13, 2015. The SEC file number is 0000899866-15-000163.. A U.S. Securities and Exchange Commission f
8/31/15 - Alexion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Aug. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on August 17, 2015. The SEC file number is 0000899866-15-000167.. A U.S. Securities and Exchange Commission f
8/31/15 - Alexion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report [Amend] (Aug. 13, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alexion Pharmaceuticals Inc. was posted on August 13, 2015. The SEC file number is 0000899866-15-000157.. A U.S. Securities and Exchange Commission f
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415